Researchers at the Kimmel Cancer Center at Jefferson have identified a protein that they say is key to helping a quarter of all breast cancers spread. The finding, reported online the week of April 9, 2007 in the journal Proceedings of the National Academy of Sciences, could be a potential target for new drugs aimed at stopping or slowing the growth and progression of breast cancer.
Building on their 2005 discovery of an enzyme that is a natural tumor suppressor, researchers at the University of California, San Diego (UCSD) School of Medicine have now identified two variants of that enzyme which could provide new targets for therapies to treat diabetes, heart and neurological disease.
Patients who undergo a minimally invasive lung cancer surgery called thoracoscopic lobectomy may derive more benefit from the chemotherapy that follows, according to Duke University Medical Center researchers.
A drug for epilepsy with a new mechanism of action is safe and effective, according to a study published in the April 10, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.
People with restless legs syndrome (RLS), especially the elderly, may be at an increased risk of developing cardiovascular disease, according to a study published in the April 10, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.
Foods rich in cocoa appear to reduce blood pressure but drinking tea may not, according to an analysis of previously published research in the April 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Common practice in the treatment of adolescent eating disorder patients has been to exclude the parents. Many experts consider parents part of the problem and thus keep them away during therapy.
An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.
A mouse model for synovial sarcoma has enabled scientists to make tremendous progress toward understanding the origin and pathogenesis of this highly aggressive soft-tissue malignancy.
Virologists in the Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM) at Virginia Tech are looking at how a genetically modified variant of Avian Newcastle disease virus (NDV) can treat human prostate cancer.